Presentation to Include Updated Interim Data from Ongoing Phase 1/2 ARIA Study of REM-422 in Adenoid Cystic Carcinoma   Watertown, Mass., October 28, 2026 – Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that an abstract featuring updated […]